Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates
- PMID: 17201458
- DOI: 10.2165/00003088-200746010-00003
Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates
Abstract
Background and objective: Caffeine treatment is widely used in nursing care to reduce the risk of apnoea in premature neonates. To check the therapeutic efficacy of the treatment against apnoea, caffeine concentration in blood is an important indicator. The present study was aimed at building a pharmacokinetic model as a basis for a medical decision support tool.
Methods: In the proposed model, time dependence of physiological parameters is introduced to describe rapid growth of neonates. To take into account the large variability in the population, the pharmacokinetic model is embedded in a population structure. The whole model is inferred within a Bayesian framework. To update caffeine concentration predictions as data of an incoming patient are collected, we propose a fast method that can be used in a medical context. This involves the sequential updating of model parameters (at individual and population levels) via a stochastic particle algorithm.
Results: Our model provides better predictions than the ones obtained with models previously published. We show, through an example, that sequential updating improves predictions of caffeine concentration in blood (reduce bias and length of credibility intervals). The update of the pharmacokinetic model using body mass and caffeine concentration data is studied. It shows how informative caffeine concentration data are in contrast to body mass data.
Conclusion: This study provides the methodological basis to predict caffeine concentration in blood, after a given treatment if data are collected on the treated neonate.
Similar articles
-
Population pharmacokinetics of caffeine in premature neonates.Eur J Clin Pharmacol. 1997;52(3):211-7. doi: 10.1007/s002280050276. Eur J Clin Pharmacol. 1997. PMID: 9218928
-
Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring.Ther Drug Monit. 2008 Dec;30(6):709-16. doi: 10.1097/FTD.0b013e3181898b6f. Ther Drug Monit. 2008. PMID: 19057373 Clinical Trial.
-
Pharmacokinetic aspects of caffeine in premature infants.Dev Pharmacol Ther. 1991;16(3):117-22. Dev Pharmacol Ther. 1991. PMID: 1914785
-
Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents.J Toxicol Environ Health A. 2004 Feb 27;67(4):297-329. doi: 10.1080/15287390490273550. J Toxicol Environ Health A. 2004. PMID: 14713563 Review.
-
Therapeutic drug monitoring in neonates.Arch Dis Child. 2016 Apr;101(4):377-81. doi: 10.1136/archdischild-2013-305309. Epub 2016 Jan 22. Arch Dis Child. 2016. PMID: 26803050 Review.
Cited by
-
Serum caffeine concentrations and short-term outcomes in premature infants of ⩽29 weeks of gestation.J Perinatol. 2015 Jun;35(6):434-8. doi: 10.1038/jp.2014.226. Epub 2014 Dec 18. J Perinatol. 2015. PMID: 25521559
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical